Podcast

FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Low Unresectable or Metastatic Breast Cancer

Author(s):

OncLive Staff

In Partnership With:

Dr Modi discusses the significance of the FDA approval of trastuzumab deruxtecan in metastatic HER2-low breast cancer, pivotal efficacy and safety data from the DESTINY-Breast04 trial, and how these findings pave the way for further progress across cancer therapy.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Shanu Modi, MD, attending physician and medical oncologist at Memorial Sloan Kettering Cancer Center. Dr Modi joined us to talk about fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-low breast cancer.

On August 5, 2022, the FDA approved the antibody-drug conjugate (ADC) trastuzumab deruxtecan in patients with unresectable or metastatic HER2-low breast cancer.

The approval was based on findings from the phase 3 DESTINY-Breast04 trial (NCT03734029), in which trastuzumab deruxtecan demonstrated a median progression-free survival of 10.1 months vs 5.4 months with standard-of-care chemotherapy in patients with hormone receptor–positive, HER2-low metastatic breast cancer. Additionally, the ADC elicited a median overall survival of 23.9 months vs 17.5 months with chemotherapy.

The most common toxicities associated with trastuzumab deruxtecan include nausea, fatigue, alopecia, vomiting, constipation, musculoskeletal pain, diarrhea, decreased appetite, and bone marrow suppression. Interstitial lung disease, though uncommon, is a potential serious adverse effect.

In our exclusive interview, Dr Modi discussed the significance of the approval in the metastatic HER2-low population, pivotal efficacy and safety data from DESTINY-Breast04, and how these findings pave the way for further progress across cancer therapy.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources, and underscores the importance of mentorship programs for community providers to ensure equitable cancer care.
In this episode of OncChats: Empowering Community Cancer Care, Drs Woodworth and Rai, discuss their collaborative approach to cancer screening, emphasizing the importance of community efforts and individual assessments in integrating genetic testing and screenings into routine practice.
In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the need for continued evaluation of prophylactic treatments like tocilizumab (Actemra) and antimicrobial measures for bispecific T-cell engagers, noting logistical and financial challenges and the importance of collaboration with community centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique toxicities like cytokine release syndrome (CRS) and the need for well-defined protocols to ensure patient safety and effective treatment.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique adverse effects, such as cytokine release syndrome and infection risks.
Related Content
Ribociclib in breast cancer | Image Credit: © Axel Kock - stock.adobe.com
October 18th 2024

Ribociclib Earns Positive CHMP Opinion in HR+/HER2– Early Breast Cancer

Francine Foss, MD, professor, medicine (hematology) and dermatology, director, Multidisciplinary T Cell Lymphoma Program, Yale School of Medicine; scientific leader, Lymphoma CRT, Yale Cancer Center
October 17th 2024

FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

Aditya Bardia, MD, MPH, FASCO, of UCLA
October 15th 2024

TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

David Weintritt, MD, FACS
October 14th 2024

Empowering Breast Surgeons: A Call for Collective Action

Josh Riggs, of Oncocyte
October 13th 2024

Assay Predicts Response to Neoadjuvant Atezolizumab Plus Chemotherapy in TNBC